US consumers are shielded from the cost of healthcare

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed.

In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed. There is, however, one recommendation that Dr. Saving alluded to, but did not emphasize, when he stated that "beneficiaries are shielded from the fiscal realities of the medical care they consume."

This situation is further exacerbated by the care delivered, especially end-of-life-care, at the patient's directive. Thus, often patients and their families want everything done because that is the only way the patient can stay in the hospital and avoid home care and costs. Often these patient directives also economically benefit the caregivers.

In the current healthcare system, there are lots of winners. The only losers are the next generation of Americans, who will be left with the tab.

Unless we use incentives and disincentives in healthcare by denying payment and/or enforcing Dr. Saving's advice that "the first dollars spent on healthcare are the responsibility of the consumer," the US healthcare delivery system is unlikely to see much improvement.

Gilbert A. Lawrence, MD, DMRT, FRCRRadiation Oncology, Faxton Hospital Cancer CenterUtica, New York

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content